Servier to buy Day One Biopharmaceuticals for $2.5 billion in cash deal

Servier, an independent international pharmaceutical group, agreed to acquire Day One Biopharmaceuticals (Nasdaq: DAWN) for $21.50 per share in cash, valuing Day One at about $2.5 billion in equity. The companies said they have signed a definitive agreement and expect the transaction to close in the second quarter of 2026, subject to customary closing conditions.

Servier said the acquisition will expand its rare oncology portfolio. Day One is a biopharmaceutical company focused on developing and commercializing targeted therapies for people with life‑threatening diseases. The announcement sent Day One shares sharply higher on Friday, with reports citing a rise of roughly 65% to about 70% as markets reacted to the deal.

Servier will pay $21.50 per share in cash, valuing Day One at approximately $2.5 billion. The companies expect the deal to close in the second quarter of 2026, subject to customary closing conditions.

Day One develops and commercializes targeted therapies for people of all ages with life‑threatening diseases, with a pipeline that includes candidates in oncology and rare disease areas.

Shareholders will receive $21.50 in cash for each Day One share if the transaction closes. The deal is final only after the customary closing conditions are satisfied.

GlobeNewsWire

SURESNES, France and BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targ...

Reuters

Independent international ‌pharmaceutical group Servier will ⁠buy Day One Biopharmaceuticals for a total equity ‌value ⁠of about $2.5 billion, the ⁠companies said on ⁠Friday.

Benzinga

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares are trading higher Friday after the company announced that Servier will acquire it for $21.50 per share in cash.

Investors Business Daily

Servier will acquire Day One Biopharmaceuticals for roughly $2.5 billion, expanding its pipeline of cancer treatments.

Newsfile Corp

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - March 6, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Day One Biopharmaceuticals, Inc. ("Day One" or the "Company") (NASDAQ: DAWN) for possible breaches of fiduciary duty and o...

Invezz

Day One Biopharmaceuticals (NASDAQ: DAWN) ripped higher on Friday morning after Servier signed a definitive agreement to acquire the California-based firm for about $2.5 billion in cash. Servier's deal rewrites DAWN's technical profile, valuing its shares at $21.5 each, which translates to a nearly...

Business Wire

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier. Under the terms of the proposed transaction...

Zacks Investment Research

Day One's stock surges 66% after Servier agrees to acquire it for $21.50 per share in a $2.5B deal, adding brain tumor drug Ojemda and oncology pipeline assets.

Show All Sources

Price

21.47

Intrinsic Value

10.33

Open

Other News

View All

4 hours ago

Ford Motor said Doug Field, its chief electric vehicle, digital and design officer, will leave the company after nearly five years helping lead its EV and software strategy. Field is a former Tesla an...

4 hours ago

<p>Anthropic, the artificial intelligence company behind Claude, has received multiple investor offers in recent weeks that would value the startup at as much as $800 billion, according to reports fro...